Low-dose extended-release minocycline outperformed doxycycline in moderate-to-severe rosacea

Design

Systematic review and meta-analysis of three randomised controlled trials

Population

643 patients with moderate-to-severe rosacea

Primary outcome

Investigator Global Assessment treatment success; inflammatory lesion count

Effect

IGA success OR 2.51 (1.80–3.49); lesions −4.56 (−6.18 to −2.93) vs doxycycline; adverse events OR 0.96 (0.55–1.66)

This meta-analysis pooled three randomised trials (643 patients) comparing minocycline hydrochloride 40 mg extended-release capsules (DFD-29) with modified-release doxycycline 40 mg, the sub-antimicrobial tetracycline most guidelines recommend for papulopustular rosacea.

Minocycline 40 mg more than doubled the odds of treatment success on the Investigator Global Assessment (OR 2.51, 95% CI 1.80 to 3.49; I² 0%) and reduced inflammatory lesion counts by 4.56 more than doxycycline (−6.18 to −2.93). A 20 mg dose did not reduce lesions significantly. Adverse events were similar (OR 0.96, 0.55 to 1.66), with one serious event, atrial fibrillation, in the minocycline group.

This gives a second sub-antimicrobial option for patients with persistent papules and pustules. Whether the 40 mg extended-release capsule is available in India is not established; conventional-release minocycline at higher doses is not equivalent and carries the familiar risks of vestibular upset, pigmentation and, rarely, autoimmune reactions.

• Consider low-dose extended-release minocycline for papulopustular rosacea that has not settled on sub-antimicrobial doxycycline.
• Use the 40 mg dose; 20 mg did not reduce inflammatory lesions.
• Do not substitute standard-release minocycline 100 mg and expect the same safety profile.
• Combine with topical therapy (ivermectin, metronidazole or azelaic acid) and trigger avoidance rather than using the tablet alone.
• Ask about palpitations at review; one atrial fibrillation event was reported.

Why it matters

Doxycycline has been the default sub-antimicrobial choice, and this suggests it is not the most effective one.

Don't overread it

Three trials of one proprietary formulation; the result does not transfer to standard minocycline.

The statistics, in plain English

An odds ratio of 2.51 means the odds of success were about two and a half times higher. I² of 0% means the three trials agreed closely. A 4.6-lesion reduction is modest but noticeable in a patient starting with 20 to 40 lesions.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.